Entera Earnings per Basic Share from 2010 to 2024

ENTX Stock  USD 2.29  0.23  9.13%   
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera main balance sheet or income statement drivers, such as Depreciation And Amortization of 97.3 K, Interest Expense of 31.4 M or Selling General Administrative of 5.2 M, as well as many exotic indicators such as Price To Sales Ratio of 79.86, Dividend Yield of 0.0 or PTB Ratio of 1.76. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules.
  
This module can also supplement Entera Bio's financial leverage analysis and stock options assessment as well as various Entera Bio Technical models . Check out the analysis of Entera Bio Correlation against competitors.
For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.

About Entera Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Entera Bio income statement, its balance sheet, and the statement of cash flows. Entera Bio investors use historical funamental indicators, such as Entera Bio's Earnings per Basic Share, to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Entera Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Pair Trading with Entera Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.

Moving against Entera Stock

  0.84BIIB Biogen Inc Earnings Call This WeekPairCorr
  0.79VRTX Vertex Pharmaceuticals Financial Report 6th of May 2024 PairCorr
  0.76AMGN Amgen Inc Financial Report 25th of April 2024 PairCorr
  0.69JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.59ABVC ABVC BiopharmaPairCorr
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Entera Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entera Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entera Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entera Bio Stock:
Check out the analysis of Entera Bio Correlation against competitors.
For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Entera Stock analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.31)
Quarterly Revenue Growth
(0.92)
Return On Assets
(0.45)
Return On Equity
(0.80)
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Entera Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.